Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. (Nasdaq: ENSC) is a clinical-stage specialty pharmaceutical company developing abuse-deterrent and overdose-prevention drug formulations through its proprietary prodrug technology platform. The company entered public markets in 2021 via a SPAC business combination, operating within the pharmaceutical and drug delivery sector. Ensysce's development pipeline applies its TAAP and MPAR platform technologies to reduce opioid prescription misuse and abuse. The Form 8-K filed February 2, 2021, is among the company's filings from the period surrounding its de-SPAC transaction. For full SPAC sponsor details, deal structure, and a complete filing archive on ENSC, sign up for access at SpacDesk.